(800) 429-3205

Submit Your Information for the BioXcel Therapeutics Lawsuit

Lead Plaintiff Deadline is September 5, 2023

If you purchased or acquired BioXcel Therapeutics securities between December 15, 2021 and June 28, 2023, please contact Berger Montague using the form below.

Please view our terms of use policy and our privacy policy.

First Name *

Last Name *

Email *

Phone Number *

Address

City

Zip

State

Are you a current or former employee of BioXcel Therapeutics?

How many shares did you purchase? Please provide ALL transactions.

What dates did you purchase? Please provide ALL dates.

What was the price per share when you purchased? Please provide ALL prices.

I agree to the terms of service

I would like to receive updates from Berger Montague

Thank you! Your form has been successfully submitted.

About the Case

According to the lawsuit, on June 29, 2023, before the market opened, BioXcel disclosed that its principal investigator for the Phase 3 TRANQUILITY II clinical trial had failed to “adhere to the informed consent form approved by the Institutional Review Board” for some subjects and failed to maintain adequate case histories for certain patients whose records were reviewed by the Food and Drug Administration (“FDA”). BioXcel further disclosed that the same principal investigator “may have fabricated” email correspondence regarding a serious adverse event. BioXcel further disclosed that the fabricated email correspondence was provided to the FDA during an on-site inspection in December 2022.

Following this news, BioXcel’s stock price fell $11.28 per share, or 63.8%, to close at $6.39 per share on June 29, 2023.

Investors who purchased or acquired BioXcel securities between December 15, 2021 and June 28, 2023, may no later than September 5, 2023, seek to be appointed as a lead plaintiff representative of the class.